|Bid||0.0780 x 38103100|
|Ask||0.0790 x 63288200|
|Day's range||0.0770 - 0.0790|
|52-week range||0.0460 - 0.1900|
|Beta (5Y monthly)||2.54|
|PE ratio (TTM)||N/A|
|Earnings date||30 Aug 2021 - 03 Sept 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited has today published positive data from a world first human clinical study, examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product for the eradication of Staphylococcus Aureus (Staph).